As a research compound, TB-500 UK is one of the most broadly studied synthetic tissue repair peptides in the published literature, with pre-clinical studies spanning dermal wound healing, corneal injury repair, cardiac biology, neurological research applications, skeletal muscle regeneration, and inflammatory pathway modulation forming the scientific basis for multiple clinical trials conducted by RegeneRx Biopharmaceuticals
The FDA confirmed that BPC-157 and TB-500 are among the seven peptides under review, alongside five others
Effects of mammalian target of rapamycin and aryl hydrocarbon receptor-mediating autophagy signaling on the balance of Th17/Treg cells during perinatal bisphenol A exposure in female offspring mice
The optimal frequency and dosage varies person to person
Considerations Slower onset: Because the peptide must traverse the nasal membranes and then enter general circulation (and eventually reach brain/central nervous system targets), the onset tends to be more gradual